Investigational drug · Phase 2
HRS-4508
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Lung Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "HRS-4508"
First trial start
2025
Sep 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-4508", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
- Lung Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-4508" as an intervention, largest first.
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsPivotal-lookingRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06555068 · 528 participants (planned) · Start Aug 12, 2024 · Primary completion Dec 2027
Drug: HRS-6209 in Combination with Fulvestrant; HRS-6209 in Combination with HRS-1358 and 9 more · For: Advanced Unresectable or Metastatic Breast Cancer; Advanced Solid Tumors
Sites: Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06598735 · 290 participants (planned) · Start Nov 5, 2024 · Primary completion Dec 30, 2027
Drug: HRS-4508 · For: Advanced Solid Tumors
Sites: Beijing, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07140393 · 120 participants (planned) · Start Oct 28, 2025 · Primary completion Oct 2027
Drug: HRS-4508+ Capecitabine; HRS-4508+ Trastuzumab and 8 more · For: Solid Tumor
Sites: Beijing, China
- A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung CancerRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07003321 · 120 participants (planned) · Start Sep 12, 2025 · Primary completion Sep 2027
Drug: HRS-4508 tablet · For: Solid Tumor
Sites: Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07232849 · 100 participants (planned) · Start Dec 4, 2025 · Primary completion Dec 2027
Drug: HRS-4508 tablet · For: Lung Cancer
Sites: Shanghai, China; Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.